铂类药物用于三阴性乳腺癌的新辅助化疗被引量：6

Neoadjuvant chemotherapy of platinum in triple negative breast cancer

下载PDF

导出

摘要三阴性乳腺癌(triple-negative breast cancer,TNBC)作为乳腺癌的一个亚型,其复发率较高而总生存率低。尽管其对于包含蒽环类和紫衫类药物为基础的新辅助化疗方案反应显著,但预后较差。目前尚未发现专门的分子及化疗药物作用靶点。铂类并非是治疗三阴性乳腺癌的常规用药,本文对铂药物用于三阴性乳腺癌新辅助化疗的现状进行综述。 Triple -negative breast cancer（ TNBC）, as a subtype of breast cancer,associate with a higher recurrence rate and a low overall survival. It is associated with a dismal prognosis despite responding remarkably well to anthracy- cline and taxane - based neoadjuvant chemotherapy. No specific molecular targets or chemotherapeutic vulnerabilities have been identified. Platinum is a chemotherapeutic agent not used routinely for breast cancer treatment. This paper explored neoadjuvant chemotherapy of platinum in TNBCs.

作者马丽张清媛

机构地区哈尔滨医科大学附属肿瘤医院内科

出处《现代肿瘤医学》 CAS 2015年第3期434-436,共3页 Journal of Modern Oncology

关键词铂类三阴性乳腺癌新辅助化疗 platinum triple negative breast cancer neoadjuvant chemotherapy

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献25

1Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J of Clin Oncol,2008,26(8):1275-1281.
2Masuda H,Baggerly KA,Wang Y,et al.Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J].Clin Cancer Res,2013,19(19):5533-5540.
3Joerger M,Thürlimann B.Chemotherapy regimens in early breast cancer:Major controversies and future outlook[J].Cancer,2013,13(2):165-178.
4Sirohi B,Arnedos M,Popat S,et al.Platinum-based chemotherapy in triple-negative breast cancer[J].Ann Oncol,2008,19(11):1847-1852.
5Staudacher L,Cottu PH,Diéras V,et al.Platinum-based chemotherapy in metastatic triple-negative breast cancer:The Institut Curie experience[J].Ann Oncol,2011,22(4):848-856.
6Petrelli F,Coinu A,Borgonovo K,et al.The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers:A systematic review and meta-analysis[J].Breast Cancer Res Treat,2014,144(2):223-232.
7Foulkes WD,Stefansson IM,Chappuis PO,et al.Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer[J].J National Cancer Institute,2003,95(19):1482-1485.
8Wang ZC,Lin M,Wei LJ,et al.Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers[J].Cancer Res,2004,64(1):64-71.
9Silver D.HIN-1 and the nosology of breast cancer[J].Cancer Biol Ther,2003,2(5):564-565.
10Lakhani SR,Reis-Filho JS,Fulford L,et al.Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype[J].Clin Cancer Res,2005,11(14):5175-5180.